Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5MPJ

1-(2-chloro-[1,1'-biphenyl]-4-yl)-N-methylethanamine

5MPJ の概要
エントリーDOI10.2210/pdb5mpj/pdb
分子名称Casein kinase II subunit alpha, ADENOSINE-5'-DIPHOSPHATE, INOSITOL HEXAKISPHOSPHATE, ... (5 entities in total)
機能のキーワードck2alpha, ck2a, fragment based drug discovery, high concentration screening, selective atp competitive inhibitors, surface entrophy reduction, transferase
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計84269.58
構造登録者
Brear, P.,De Fusco, C.,Georgiou, K.,Iegre, J.,Sore, H.,Hyvonen, M.,Spring, D. (登録日: 2016-12-16, 公開日: 2017-05-24, 最終更新日: 2024-01-17)
主引用文献De Fusco, C.,Brear, P.,Iegre, J.,Georgiou, K.H.,Sore, H.F.,Hyvonen, M.,Spring, D.R.
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066.
Bioorg. Med. Chem., 25:3471-3482, 2017
Cited by
PubMed Abstract: Recently we reported the discovery of a potent and selective CK2α inhibitor CAM4066. This compound inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket). Here we describe in detail the journey that led to the discovery of CAM4066 using the challenging fragment linking strategy. Specifically, we aimed to develop inhibitors by linking a high-affinity fragment anchored in the αD site to a weakly binding warhead fragment occupying the ATP site. Moreover, we describe the remarkable impact that molecular modelling had on the development of this novel chemical tool. The work described herein shows potential for the development of a novel class of CK2 inhibitors.
PubMed: 28495381
DOI: 10.1016/j.bmc.2017.04.037
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.14 Å)
構造検証レポート
Validation report summary of 5mpj
検証レポート(詳細版)ダウンロードをダウンロード

229183

件を2024-12-18に公開中

PDB statisticsPDBj update infoContact PDBjnumon